La cadena de opciones muestra datos clave de las opciones de acciones de AIM ImmunoTech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para AIM ImmunoTech..

AIM ImmunoTech (AMEX:AIM) Bolsa, Cadena de Opciones

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Acciones que se mueven

ARHS

BASE

CAPR

CDNA

CTOR

DGLY

HLMN

ICCT

NTHI

TILE

Xos sorprende al mercado con sólidos resultados en 2024 y hace subir sus acciones antes de la apertura. Descubre más movimientos aquí.

Acciones de Xos (XOS) suben alrededor de un 9%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

<h3>Gainers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) stock moved upwards by 238.3% to $1.87 during Tuesday's regular session. The market value of their outstanding shares is at $17.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 59.3% to $1.18. The market value of their outstanding shares is at $1.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares rose 29.03% to $0.71. The company's market cap stands at $18.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares rose 25.74% to $0.69. The market value of their outstanding shares is at $16.6 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares increased by 19.73% to $16.59. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares rose 16.91% to $8.64. The company's market cap stands at $161.5 million. As per the news, the Q2 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares fell 53.8% to $3.33 during Tuesday's regular session. The company's market cap stands at $5.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 26.05% to $3.35. The market value of their outstanding shares is at $10.7 million. The company's, Q2 earnings came out yesterday. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) shares declined by 24.77% to $4.86. The market value of their outstanding shares is at $831.3 million. As per the press release, Q2 earnings came out today. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 21.96% to $0.35. The company's market cap stands at $18.4 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares decreased by 21.42% to $3.18. The market value of their outstanding shares is at $25.3 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAKA#NASDAQ">NAKA</a>) shares declined by 21.35% to $8.33. The company's market cap stands at $80.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CLDI

DRRX

EKSO

MBRX

NAKA

PRPH

SLRX

SONN

SRPT

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.
The Dow traded down 0.40% to 44,658.06 while the NASDAQ fell 0.22% to 21,131.59. The S&amp;P 500 also fell, dropping, 0.20% to 6,376.82.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Real estate shares jumped by 1.5% on Tuesday.
In trading on Tuesday, industrials stocks dipped by 1.2%.
Top Headline
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported downbeat second-quarter 2025 earnings on Tuesday and reestablished its 2025 guidance.
The insurance giant reported adjusted earnings of $4.08, down from $6.80 a year ago, missing the consensus of $4.95. Revenues increased 13% year over year to $111.62 billion, missing the consensus of $111.69 billion.
UnitedHealth reestablished its fiscal year 2025 guidance, with adjusted earnings of at least $16 per share versus a consensus of $22.33 and sales guidance of $445.5 billion-$448 billion compared to the analyst estimate of $449.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares shot up 271% to $2.0498 after Bausch Health announced plans to acquire the company.</li>
<li>Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) got a boost, surging 25% to $17.27 after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares were also up, gaining 102% to $1.35 after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares dropped 54% to $3.3169 after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.</li>
<li>Shares of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) were down 21% to $54.34 after the company lowered its 2025 sales outlook, citing reduced growth expectations for Wegovy and Ozempic in the US and weaker Wegovy penetration.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 42% to $0.0487 after the company announced a 250-to-1 share consolidation.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $67.55 while gold traded up 0.5% at $3,326.10.
Silver traded up 0.2% to $38.28 on Tuesday, while copper rose 0.4% to $5.6395.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.46%, while Spain's IBEX 35 Index gained 0.91%. London's FTSE 100 rose 0.80%, Germany's DAX 40 gained 1.15% and France's CAC 40 rose 0.87% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.79%, Hong Kong's Hang Seng falling 0.15%, China's Shanghai Composite rising 0.33% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>The number of job openings declined by 275,000 to 7.437 million in June, compared to market expectations of 7.55 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 2.8% year-over-year for May.</li>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $907.7 billion in June.</li>
<li>The U.S. trade deficit in goods shrank by $10.4 billion to $86 billion in June.</li>
<li>The Dallas Fed&#8217;s general business activity index rose 6.4 points to a reading of 2 in July.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

STAI

WLGS

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 0.4% on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.02% to 44,828.67 while the NASDAQ rose 0.41% to 21,264.97. The S&amp;P 500 also rose, gaining, 0.18% to 6,401.25.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Tuesday.
In trading on Tuesday, health care stocks dipped by 1.2%.
Top Headline
The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) reported better-than-expected earnings for the second quarter on Tuesday.
The company posted quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.42 per share. The company reported quarterly sales of $20.889 billion which beat the analyst consensus estimate of $20.765 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares shot up 360% to $2.54 after Bausch Health announced plans to acquire the company.</li>
<li>Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) got a boost, surging 156% to $1.90. the company announced it has been granted an extension to meet Nasdaq&#8217;s equity and bid price standards.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares were also up, gaining 79% to $1.1999 after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares dropped 56% to $3.19 after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.</li>
<li>Shares of Profusa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFSA#NASDAQ">PFSA</a>) were down 51% to $0.9501.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 44% to $0.0471 after the company announced a 250-to-1 share consolidation.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $67.55 while gold traded up 0.2% at $3,314.90.
Silver traded up 0.1% to $38.230 on Tuesday, while copper rose 0.6% to $5.6510.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.6%, while Spain's IBEX 35 Index gained 1.1%. London's FTSE 100 rose 0.9%, Germany's DAX 40 gained 1.2% and France's CAC 40 rose 1.1% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.79%, Hong Kong's Hang Seng falling 0.15%, China's Shanghai Composite rising 0.33% and India's BSE Sensex gaining 0.55%.
Economics
<ul class="wp-block-list">
<li>The number of job openings declined by 275,000 to 7.437 million in June, compared to market expectations of 7.55 million.</li>
<li>The S&amp;P CoreLogic Case-Shiller Home Price Index increased 2.8% year-over-year for May.</li>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $907.7 billion in June.</li>
<li>The U.S. trade deficit in goods shrank by $10.4 billion to $86 billion in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shuterstock

PFSA

US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings

WIIM

AIM ImmunoTech shares are trading lower after the company announced a $8 million public offering consisting of shares as well as class E and F warrants.

Offerings

AIM ImmunoTech Announces Pricing Of 2M Shares, Class E Warrants And Class F Warrants At Combined Public Offering Price; Gross Proceeds $8M

<h3>Gainers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares moved upwards by 270.9% to $2.05 during Tuesday's pre-market session. The company's market cap stands at $17.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 150.97% to $1.86. The company's market cap stands at $1.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock rose 50.14% to $0.83. The market value of their outstanding shares is at $18.9 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock increased by 42.43% to $2.92. The company's market cap stands at $1.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares rose 37.92% to $19.12. The market value of their outstanding shares is at $1.3 billion. </li>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock rose 27.54% to $108.3. The market value of their outstanding shares is at $2.4 billion. As per the news, the Q2 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) stock decreased by 39.6% to $4.35 during Tuesday's pre-market session. The company's market cap stands at $5.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 24.51% to $3.42. The company's market cap stands at $10.7 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock fell 20.96% to $54.54. The market value of their outstanding shares is at $306.5 billion. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock decreased by 15.5% to $6.6. The market value of their outstanding shares is at $421.5 million. As per the news, the Q2 earnings report came out today. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock fell 15.1% to $5.49. The market value of their outstanding shares is at $831.3 million. As per the press release, Q2 earnings came out today. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock decreased by 14.15% to $0.19. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FULC

SCNI

VTAK

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results, raised its FY25 guidance, and issued third-quarter <a href="https://www.benzinga.com/markets/earnings/25/07/46676131/celestica-stock-surges-on-q2-earnings-beat-company-raises-2025-outlook-on-strengthening-demand">guidance above estimates</a>.
Celestica reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.22 per share. The company reported quarterly sales of $2.893 billion which beat the analyst consensus estimate of $2.652 billion.
Celestica jumped 12.1% to $194.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares gained 279.1% to $2.81 in pre-market trading. The company recently announced it has been granted an extension to meet Nasdaq&#8217;s equity and bid price standards.</li>
<li>Scinai Immunotherapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) rose 66.8% to $3.42 in pre-market trading.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) climbed 39.3% to $0.9350 in pre-market trading after the company announced it entered into a non-binding letter of intent with Visiontec Systems for the planned purchase of additional Sentinel fixed gantry CT inspection systems.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) shares jumped 38% to $0.21 in pre-market trading after falling 13% on Monday.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) gained 33.6% to $18.55 in pre-market trading following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta's gene therapy for Duchenne Muscular Dystrophy.</li>
<li>Fulcrum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) surged 20.7% to $9.43 in pre-market trading after the company announced it will present topline results from the 12 mg dose cohort of its Phase 1b PIONEER trial.</li>
<li>Chart Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) surged 16.5% to $200.50 in pre-market trading.</li>
<li>Cellectis S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) gained 15.5% to $3.30 in pre-market trading. Cellectis will report its second quarter financial results on Aug. 4.</li>
<li>Donegal Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGICB#NASDAQ">DGICB</a>) rose 13.5% to $17.30 in pre-market trading after declining 3% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) dipped 40.9% to $4.25 in pre-market trading. AIM ImmunoTech recently announced mid-year data from its Phase 2 DURIPANC trial.</li>
<li>Bakkt Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) declined 40% to $10.31 in pre-market trading after the company announced the pricing of $75 million public offering.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) dipped 37.5% to $0.0529 in pre-market trading. Wang &amp; Lee Group announced a 250-to-1 shares consolidation.</li>
<li>Profusa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFSA#NASDAQ">PFSA</a>) shares tumbled 34.5% to $1.27 in pre-market trading after gaining 185% on Monday.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) fell 27.3% to $3.27 in pre-market trading after the company announced second-quarter results.</li>
<li>Leslie&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) fell 27.1% to $0.47 in pre-market trading after the company announced preliminary third quarter fiscal financial results.</li>
<li>VisionWave Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWAV#NASDAQ">VWAV</a>) declined 25.7% to $8.17 in pre-market trading. VisionWave Holdings shares jumped 368% on Monday after the company announced that it has secured $55 million in growth capital to scale its AI defense solutions.</li>
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) fell 19.7% to $0.0939 in pre-market trading. Wag! Group shares fell more than 6% on Monday after the company announced it has initiated Chapter 11 proceedings in a Delaware court.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) shares fell 16.3% to $81.93 in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 earnings guidance.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) fell 13.8% to $7.88 in pre-market trading after the company issued third-quarter guidance below estimates.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46656981/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CLLS

DGICB

GTLS

HLIT

LESL

SISI

VWAV

Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

AIM stock has given up its prior gain. AIM ImmunoTech shares were trading higher after the company announced mid-year data from its Phase 2 DURIPANC trial.

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
The Dow traded up 0.07% to 44,932.70 while the NASDAQ rose 0.28% to 21,167.71. The S&amp;P 500 also rose, gaining, 0.09% to 6,394.33.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Energy shares jumped by 0.9% on Monday.
In trading on Monday, materials stocks dipped by 1.1%.
Top Headline
The United States has temporarily halted restrictions on technology exports to China, according to a Monday report from the Financial Times. This pause is intended to prevent disruptions to ongoing trade discussions with Beijing and to bolster President Donald Trump's push for a meeting with Chinese President Xi Jinping later this year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) shares shot up 600% to $62.10 after the company announced a $500 million private placement.</li>
<li>Shares of Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) got a boost, surging 167% to $36.80 after the company released topline results from its PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares were also up, gaining 41% to $11.82 after the company announced mid-year data from its Phase 2 DURIPANC trial.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) shares dropped 84% to $0.21. Quhuo announced a strategic partnership with NIU World to jointly establish a new chain brand incubation platform focused on fresh beef, built upon a localized supply chain in China.</li>
<li>Shares of Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) were down 63% to $0.1271 after the company announced it has agreed to sell Tecelra and other assets related to its cell therapy products for $55 million.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) was down, falling 44% to $1.1200 after the company announced a $7.5 million public offering.</li>
</ul>
Commodities In commodity news, oil traded up 2.2% to $66.57 while gold traded down 0.9% at $3,306.90.
Silver traded down 0.3% to $38.235 on Monday, while copper fell 1% to $5.7285.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.19%, while Spain's IBEX 35 Index slipped 0.09%. London's FTSE 100 fell 0.57%, Germany's DAX 40 declined 0.89% and France's CAC 40 fell 0.37% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 falling 1.10%, Hong Kong's Hang Seng gaining 0.68%, China's Shanghai Composite rising 0.12% and India's BSE Sensex falling 0.70%.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

ADAP

CELC

SIDU

VAPE

Crude Oil Gains 2%; CEA Industries Shares Spike Higher

Biotechnology firms are increasingly turning to innovative combination therapies to <a href="https://www.benzinga.com/general/biotech">tackle hard-to-treat cancers</a>, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
The study is evaluating Ampligen (rintatolimod) in combination with AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), in metastatic pancreatic cancer patients with <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noopener">stable disease following FOLFIRINOX treatment</a>.
The DURIPANC study, a collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands, is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion.
As of the mid-year report, 14 subjects had been enrolled in DURIPANC. The primary objective of the study is to determine the clinical benefit rate of the combination therapy; the secondary/exploratory objectives include assessing overall survival (OS), progression-free survival (PFS), and initiating immune monitoring using available tissue biopsies <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46657801/aim-immunotech-reports-positive-mid-year-safety-and-efficacy-data-from-phase-2-study-evaluating-am" rel="noreferrer noopener">and peripheral immune profiling</a>.
Following FOLFIRINOX, maintenance or second-line immunotherapies have historically shown limited survival benefit in comparison trials. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS:
<ul class="wp-block-list">
<li>No significant toxicity, an encouraging safety profile for a post-chemo setting.</li>
<li>Around 21% of patients have progression-free survival (PFS) of over 6 months (3/14), with an additional 21% not yet progressed.</li>
<li>The majority (64%) of eligible patients had an overall survival of over 6 months, which is better than expected in this setting.</li>
</ul>
AIM has developed an intellectual property plan specific to pancreatic cancer that includes a recently issued U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection to Aug. 9, 2039.
AIM Price Action: AIM ImmunoTech shares were up 36.79% at $11.49 at the time of publication on Monday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46657284/palantirs-next-stop-is-200-says-jim-cramer-as-pltr-glides-like-a-knife-through-butter" target="_blank" rel="noreferrer noopener">Palantir&#8217;s Next Stop Is $200, Says Jim Cramer As PLTR Glides &#8216;Like A Knife Through Butter&#8217;</a></li>
</ul>
Photo: jittawit21/Shutterstock

Biotech

Health Care

General

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 50 points on Monday.
Following the market opening Tuesday, the Dow traded down 0.14% to 44,837.21 while the NASDAQ rose 0.35% to 21,181.60. The S&amp;P 500 also rose, gaining, 0.07% to 6,393.09.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46628925/top-2-materials-stocks-that-may-fall-off-a-cliff-this-month">Top 2 Materials Stocks That May Fall Off A Cliff This Month</a>
Leading and Lagging Sectors Energy shares jumped by 0.9% on Monday.
In trading on Monday, materials stocks dipped by 1.3%.
Top Headline
Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) reported better-than-expected earnings for the second quarter.
The company posted quarterly earnings of 66 cents per share which beat the analyst consensus estimate of 64 cents per share. The company reported quarterly sales of $11.36 billion which missed the analyst consensus estimate of $14.19 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) shares shot up 513% to $54.37 after the company announced a $500 million private placement.</li>
<li>Shares of Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) got a boost, surging 220% to $44.10 after the company released topline results from its PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) shares were also up, gaining 77% to $14.85 after the company announced mid-year data from its Phase 2 DURIPANC trial.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) shares dropped 77% to $0.31. Quhuo announced a strategic partnership with NIU World to jointly establish a new chain brand incubation platform focused on fresh beef, built upon a localized supply chain in China.</li>
<li>Shares of Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) were down 64% to $0.1256 after the company announced it has agreed to sell Tecelra and other assets related to its cell therapy products for $55 million.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) was down, falling 44% to $1.1350 after the company announced a $7.5 million public offering.</li>
</ul>
Commodities In commodity news, oil traded up 2.3% to $66.66 while gold traded down 0.6% at $3,316.50.
Silver traded down 0.4% to $38.205 on Monday, while copper fell 0.8% to $5.7395.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.1%, while Spain's IBEX 35 Index rose 0.1%. London's FTSE 100 fell 0.5%, Germany's DAX 40 declined 0.7% and France's CAC 40 fell 0.2% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 falling 1.10%, Hong Kong's Hang Seng gaining 0.68%, China's Shanghai Composite rising 0.12% and India's BSE Sensex falling 0.70%.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46658582/top-2-real-estate-stocks-that-may-collapse-this-quarter">Top 2 Real Estate Stocks That May Collapse This quarter</a></li>
</ul>
Photo via Shutterstock

US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings

AIM ImmunoTech shares are trading higher after the company announced mid-year data from its Phase 2 DURIPANC trial.

<a href="https://www.globenewswire.com/Tracker?data=GoUgY3MXoIYLTNyvEdIp04-hsrWgoBmgTt1G4BFAC1ZgUjct2dFEx0JOH7uuQYs6kWgxgU0hSD8oQExNL_w_6I7quEeTprD3yRVl2-du1us=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen&#xAE; (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi&#xAE; (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (the "DURIPANC" study) (See: <a href="https://www.globenewswire.com/Tracker?data=S1SeHNOiJEjBI0gjPa2sKZDlYIoLifcxMeZoVi1FqyN-SB8DNb_wUHuMzesbv_pHYMUTVIW-30PMcHaJe1PEVUG7bYPtOxFUCpB5YG2J0RRnBChgzgXmmigcUMY4CG5cp-shQDBrWapoewgO0HY2CA==">ClinicalTrials.gov NCT05927142</a>).
The DURIPANC study — which is a joint collaboration with AstraZeneca and Erasmus Medical Center ("Erasmus MC") in the Netherlands — is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. A total of 14 subjects have been enrolled in DURIPANC as of the mid-year report. The primary objective of the study is the clinical benefit rate of the combination therapy; the secondary/exploratory objectives include assessing overall survival (OS), progression-free survival (PFS) and initiating immune-monitoring using available tissue biopsies and peripheral immune profiling.

AIM ImmunoTech Announces Mid-Year Data From Phase 2 DURIPANC Trial Of Ampligen And AstraZeneca's Imfinzi In Metastatic Pancreatic Cancer Patients Post-FOLFIRINOX

AIM ImmunoTech Receives NYSE Notification Regarding Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Announces It Has Resumed Trading On NYSE

Reported Friday, AIM ImmunoTech Receives NYSE American Delisting Notice Due To Low Stock Price, Plans To Appeal

AIM ImmunoTech shares are trading lower after the company announced it entered into a $3 million equity distribution agreement with Maxim Group for an at-the-market offering

AIM ImmunoTech Enters $3M Equity Distribution Agreement With Maxim Group For "At the Market" Offering

U.S. stocks traded lower this morning, with the Dow Jones index dipping more than 1,100 points on Friday. China unveiled a retaliatory 34% tariff on U.S. goods—mirroring the rate announced by President Donald Trump on Wednesday—deepening fears of a full-blown trade war.
The Dow traded down 2.82% to 39,401.43 while the NASDAQ fell 3.59% to 15,955.66. The S&amp;P 500 also fell, dropping, 3.20% to 5,223.96.
Check This Out: <a href="https://www.benzinga.com/25/04/44644881/top-3-financial-stocks-that-may-fall-off-a-cliff-in-april">Top 3 Financial Stocks That May Fall Off A Cliff In April</a>
Leading and Lagging Sectors Consumer staples shares fell by just 0.5% on Friday.
In trading on Friday, energy shares tumbled by 5.2%.
Top Headline
In March, nonfarm payrolls surged by 228,000, the Bureau of Labor Statistics reported Friday. The outcome is well above the three-month average of 195,000 and topped economists&#8217; forecasts of 135,000. February's employment growth was downwardly revised to 117,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares shot up 84% to $0.8522.</li>
<li>Shares of iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>)got a boost, surging 79% to $7.59.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) shares were also up, gaining 51% to $9.77.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NeuroOne Medical Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares dropped 44% to $0.4781 lower following its $8 million stock offering.</li>
<li>Shares of Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) were down 28% to $0.3027.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) was down, falling 39% to $0.0723.</li>
</ul>
Commodities In commodity news, oil traded down 7.8% to $61.72 while gold traded down 1% at $3,090.30.
Silver traded down 4.1% to $30.665 on Friday, while copper fell 6.9% to $4.4950.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 4.2%, Germany's DAX 40 dipped 4.2% and France's CAC 40 fell 3.8%. Spain's IBEX 35 Index fell 5.1%, while London's FTSE 100 dipped 3.8%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 dipping 2.75% and India's BSE Sensex falling 1.22%.
Economics
<ul>
<li>In March, nonfarm payrolls surged by 228,000, the Bureau of Labor Statistics reported Friday. The outcome is well above the three-month average of 195,000 and topped economists&#8217; forecasts of 135,000. February's employment growth was downwardly revised to 117,000.</li>
<li>The unemployment rate unexpectedly inched higher from 4.1% to 4.2%, defying expectations for no change.</li>
<li>Average hourly earnings increased 0.3% from February&#8217;s pace, as predicted, and rose 3.8% year-over-year, marginally lower than the 3.9% predicted.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo via Shutterstock

NMTC

PTIX

USAR

Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March

Shares of Xos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) rose sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/XOS">reported 2024 results</a>.
The company reported its 2024 revenue surged to $56 million, compared to $44.5 million in 2023. The company delivered 297 units in 2024, up from 283 units in the previous year. Its GAAP gross margins improved from a negative 2.9% in 2023 to a positive 7.1% in 2024.
Xos shares jumped 9% to $3.75 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 75.3% to $0.1402 in pre-market trading after falling over 22% on Friday.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) rose 50.4% to $1.00 in pre-market trading.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 50% to $1.20 in pre-market trading after falling around 5% on Friday.</li>
<li>iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) gained 37.2% to $0.3910 in pre-market trading after dipping more than 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 30.1% to $4.45 in pre-market trading after gaining around 12% on Friday. QuantaSing Group, last week, expanded into pop toys market with strategic acquisition of Letsvan.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) rose 19.2% to $0.8701 in pre-market trading after declining 5% on Friday.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) surged 15.5% to $0.1397 in pre-market trading. AIM ImmunoTech, last week, posted upbeat FY 2024 results.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 7.7% to $17.96 in pre-market after declining 8% on Friday.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 6.3% to $20.99 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares fell 48.3% to $0.0176 in pre-market trading after dipping 23% on Friday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) fell 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) declined 19.5% to $7.00 in pre-market trading.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) fell 18.7% to $0.35 in pre-market trading. Enzo Biochem announced plans to voluntarily delist its common stock from the new York Stock Exchange.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) dipped 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares dipped 17.7% to $14.00 in pre-market trading.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares tumbled 15.3% to $0.0288 in pre-market trading after falling over 20% on Friday.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell 14.3% to $15.40 in today's pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Press Releases

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Legal

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Events

JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

IPOs

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

AIMI

AIMID

AKTX

AMIX

CNSP

NUWE

NVNO

OTLK

PALI

SNTI

Aditxt

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Celularity

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

Liminatus Pharma

Medicus Pharma

Oragenics

Onconetix

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Soligenix

Theriva Biologics

Ascendiant Capital

Maxim Group

Comments

AIM ImmunoTech

AIM ImmunoTech (AIM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL